German biotech companies expect that their situation will continue to improve this year. Early indicators show that a more favourable future business situation and an increase in jobs and R&D investments can be expected.
BIO Deutschland has called for recognition of biotechnology by the political sphere. On the occasion of a meeting of the Bundestag Committee on Technology Assessment in January, Peter Heinrich, Chairman of the Board of BIO Deutschland stated, “As a ‘land of ideas’ that boasts about its technological innovative strength, Germany cannot afford to be even more hostile to technology. Moreover, this is at the cost of better healthcare with new medications, healthier food, and environmental protection.”
BIO Deutschland is pleased that in the health research programme presented in the cabinet at the beginning of January, the Federal Government expressly mentioned the importance of young, innovative biotechnology companies in the development of efficient and effective medications and recognised their role in the necessary technology transfer from institutional research to the economy.
Meeting of the Interdisciplinary Working Group on German-Chinese Cooperation at the Federal Ministry of Economics and Technology
In January, the Federal Ministry of Economics and Technology in Berlin invited the heads of the sub-working group on the medical economy and biotechnology of the German-Chinese Working Group and representatives of the association to a planning meeting on coordinating and organising further steps.